Abstract
Stroke is the third common cause of death and the most common cause of adult disability. Approximately 80% of all strokes are ischemic (brain infarction). The only approved acute therapy is intravenous thrombolysis with tissue plasminogen activator within 3 h of symptom onset but only a small percentage of all ischemic stroke patients can receive this therapy. Therefore, novel therapeutic approaches directed at the pathophysiological mechanisms involved in ischemic brain injury are urgently needed. To this end several experimental stroke models were developed. These models are indispensable for understanding the pathophysiology of brain ischemia and to develop novel drugs and investigative methodology. This review considers the most commonly used ischemic stroke models (including preconditioning models) in rodents emphasizing their advantages and disadvantages. Since none of the models can perfectly simulate human stroke, researchers must interpret experimental findings carefully.
Keywords: Rat, mouse, infarction, brain, ischemia, therapy, ischemic tolerance, magnetic resonance imaging, preconditioning
Current Pharmaceutical Design
Title: Rodent Models of Ischemic Stroke: A Useful Tool for Stroke Drug Development
Volume: 14 Issue: 4
Author(s): Aysan Durukan, Daniel Strbian and Turgut Tatlisumak
Affiliation:
Keywords: Rat, mouse, infarction, brain, ischemia, therapy, ischemic tolerance, magnetic resonance imaging, preconditioning
Abstract: Stroke is the third common cause of death and the most common cause of adult disability. Approximately 80% of all strokes are ischemic (brain infarction). The only approved acute therapy is intravenous thrombolysis with tissue plasminogen activator within 3 h of symptom onset but only a small percentage of all ischemic stroke patients can receive this therapy. Therefore, novel therapeutic approaches directed at the pathophysiological mechanisms involved in ischemic brain injury are urgently needed. To this end several experimental stroke models were developed. These models are indispensable for understanding the pathophysiology of brain ischemia and to develop novel drugs and investigative methodology. This review considers the most commonly used ischemic stroke models (including preconditioning models) in rodents emphasizing their advantages and disadvantages. Since none of the models can perfectly simulate human stroke, researchers must interpret experimental findings carefully.
Export Options
About this article
Cite this article as:
Durukan Aysan, Strbian Daniel and Tatlisumak Turgut, Rodent Models of Ischemic Stroke: A Useful Tool for Stroke Drug Development, Current Pharmaceutical Design 2008; 14 (4) . https://dx.doi.org/10.2174/138161208783497688
DOI https://dx.doi.org/10.2174/138161208783497688 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cell and Gene Therapies for Refractory Epilepsy
Current Neuropharmacology Pathogenesis of Stroke-Like Episodes in MELAS: Analysis of Neurovascular Cellular Mechanisms
Current Neurovascular Research Protective Effects of Caffeic Acid and the Alzheimer's Brain: An Update
Mini-Reviews in Medicinal Chemistry Towards the Management of Inflammation: Recent Developments of mPGES-1 Inhibitors
Recent Patents on CNS Drug Discovery (Discontinued) Pharmacotherapy in Type 2 Diabetes: A Functional Schema for Drug Classification
Current Diabetes Reviews EPA and DHA Differentially Affect In Vitro Inflammatory Cytokine Release by Peripheral Blood Mononuclear Cells from Alzheimer’s Patients
Current Alzheimer Research Anti-Angiogenic Treatment for Exudative Age-Related Macular Degeneration: New Strategies are Underway
Current Angiogenesis (Discontinued) MicroRNAs in Organogenesis and Disease
Current Molecular Medicine Inhibitors of Endocannabinoid Degradation as Potential Therapeutic Agents: An Update
Medicinal Chemistry Reviews - Online (Discontinued) Imaging of Cyclooxygenase-2 (COX-2) Expression: Potential Use in Diagnosis and Drug Evaluation
Current Pharmaceutical Design Pharmacological Approach of Pistacia Vera Fruit to Assess Learning and Memory Potential in Chemically-Induced Memory Impairment in Mice
Central Nervous System Agents in Medicinal Chemistry Pharmacodynamics and Pharmacokinetics of Antifungals for Treatment of Invasive Aspergillosis
Current Pharmaceutical Design Hypoxia-Inducible Factor-1α Contributes to Brain Edema after Stroke by Regulating Aquaporins and Glycerol Distribution in Brain
Current Neurovascular Research Macrophage Derived Cystatin B/Cathepsin B in HIV Replication and Neuropathogenesis
Current HIV Research Tauopathies – Focus on Changes at the Neurovascular Unit
Current Alzheimer Research Non-peptide Antagonists and Agonists of the Bradykinin B2 Receptor
Current Medicinal Chemistry Editorial:Brain Hemorrhages and Future Management
Current Drug Targets Novel Antiinflammatory and Antiinfective Agents
Anti-Infective Agents in Medicinal Chemistry Exploiting Substrate Recognition for Selective Inhibition of Protein Kinases
Current Pharmaceutical Design Role of Stromal-Derived Factor-1 in Mesenchymal Stem Cell Paracrinemediated Tissue Repair
Current Stem Cell Research & Therapy